Enliven Therapeutics, Inc. (ELVN)
49.45
-0.79
(-1.57%)
USD |
NASDAQ |
Sep 18, 16:00
49.45
0.00 (0.00%)
After-Hours: 20:00
Enliven Therapeutics Cash from Operations (Quarterly) : -18.53M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -18.53M |
| March 31, 2026 | -19.29M |
| December 31, 2025 | -15.84M |
| September 30, 2025 | -13.28M |
| June 30, 2025 | -17.06M |
| March 31, 2025 | -24.13M |
| December 31, 2024 | -17.20M |
| September 30, 2024 | -12.19M |
| June 30, 2024 | -20.44M |
| March 31, 2024 | -23.36M |
| December 31, 2023 | -12.48M |
| September 30, 2023 | -15.89M |
| June 30, 2023 | -12.05M |
| March 31, 2023 | -20.84M |
| Date | Value |
|---|---|
| December 31, 2022 | -11.64M |
| September 30, 2022 | -6.447M |
| June 30, 2022 | -7.124M |
| March 31, 2022 | -10.36M |
| December 31, 2021 | -12.48M |
| September 30, 2021 | -10.90M |
| June 30, 2021 | -10.36M |
| March 31, 2021 | -13.02M |
| December 31, 2020 | -8.269M |
| September 30, 2020 | -10.35M |
| June 30, 2020 | -9.256M |
| March 31, 2020 | -9.527M |
| December 31, 2019 | -8.042M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Definium Therapeutics, Inc. | -52.33M |
| Cocrystal Pharma, Inc. | -2.536M |
| CNBX Pharmaceuticals, Inc. | -0.0477M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -48.30M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -441.57M |
| Cash from Financing (Quarterly) | 463.42M |
| Free Cash Flow | -67.04M |
| Free Cash Flow Per Share (Quarterly) | -0.2815 |
| Free Cash Flow to Equity (Quarterly) | -19.84M |
| Free Cash Flow to Firm (Quarterly) | -18.63M |
| Free Cash Flow Yield | -2.14% |